The demand for PET continued to grow in 2004, reaching 1 million procedures, an increase of 46% for the year. Procedure volume is expected to rise to 3.2 million procedures by 2010, according to a recent study by market research firm Bio-Tech Systems.
The procedure growth is coming from new indications in oncology, as well as expanded use of PET in lung cancer, breast cancer, colon cancer, lymphoma, and melanoma. Although the dominant focus of PET is still in oncology, the number of cardiology applications has increased as the modality is increasingly being used to diagnose myocardial viability and as a follow-up to equivocal SPECT studies, the Las Vegas, NV-based company said.
This has stimulated sales of FDG, while reducing the cost per dose. FDG sales of $270 million in 2004 were up 34% from $202 million in 2003. These sales should reach $795 million by 2010, based solely on present utilization, Bio-Tech forecast.
The firm reported that there were 302 PET scanners sold in the U.S. and 476 scanners sold worldwide in 2004, with revenues of $476.1 million and $756.8 million, respectively. Bio-Tech noted that both U.S. and international users have adopted PET/CT very rapidly.
In 2004, PET/CT comprised about 95% of total billings. By 2010, the firm forecast that U.S. bookings will increase to 510 units with sales of $760 million. International bookings will reach 850 units and $1.275 billion in sales volume.
The publication, "Report 220: The Market for PET Radiopharmaceuticals and PET Imaging," is available on the company's Web site, at www.biotechsystems.com.
By AuntMinnie.com staff writers
July 6, 2005
Related Reading
Radiopharmaceuticals market to reach $3.2 billion by 2010, June 29, 2005
Changing market for PET brings challenges and opportunities, September 30, 2004
Contrast media market set to double by 2009, June 16, 2004
Copyright © 2005 AuntMinnie.com
